2Glover D, Glick JH,Weiler C. et al. Phise 1/2 trials of WR - 2721 and cis - platinum[J ]. Int J Radar Oncol biolPhys, 1988,12 : 1509 - 1512.
3Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR- 1065 and cis - platinum[J]. INT J R adiat Oncol BiolPhys, 1989, 16: 1201 - 1204.
4Hellstrom- Lindberg E. Treatment of adult myelodysplastic syndromes [J]. Int J Hematol, 1999,70(3):141-154.
5Kemp G, Rose P, Lurain J,et al. Amifostine pretreatment for protection against cyclophosphamide - induced and eisplatin - induced toxicities: results of a randornized conreol trial in patiennnnnts with advanced ovarian cancer[J]. J Clin Oncol, 1996, 14(7):2101- 2112.
6Buntzel J , Kuttnerk , Forhlich D, et al. Selective cytoprotection with amifostine in concttrrent radiochemotherapy for head and neck cancer [J]. Ann Oncol, 1998,9(5) :505- 509.
7Cazzola M. Alternatives toeonventional or myeloablative chemotherapy in myelodysplastic syndrome[J]. Int J Hemayol, 2000,72(2) : 134 - 138.
